Medical therapy of secondary hyperparathyroidism in chronic kidney disease: Old and new drugs

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 16, 2006, Pages 2215-2224

  De Francisco, Angel L M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Calcimimetics; Hyperparathyroidism; Hyperplasia vitamin D; Parathyroid glands pathology

Indexed keywords

NEW DRUG;

CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; METHODOLOGY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC;

EID: 34548450990     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.16.2215     Document Type: Review

References (106)

1. DE FRANCISCO AL: Secondary hyperparathyroidism: review of the disease and its treatment. Clin. Ther. (2004) 26(12):1976-1993.
2. GANESH SK, STACK AG, LEVIN NW, HULBERT-SHEARON T, PORT FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. (2001) 12(10):2131-2138.
3. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31(4):607-617. •• This key publication describes the associations between abnormal serum calcium, phosphorus and calcium-phosphate ion product with morbidity and mortality in dialysis patients.
4. BLOCK GA, KLASSEN PS, LAZARUS JM et al.: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15(8):2208-2218.
5. YOUNG EW, ALBERT JM, SATAYATHUM S et al.: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. (2005) 67(3):1179-1187. (Pubitemid 41623345)
6. EKNOYAN G, LEVIN A, LEVIN N: Bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S1-s201. •• The K/DOQI guidelines for management of patients with chronic kidney disease.
7. YOUNG EW, AKIBA T, ALBERT JM et al.: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. (2004) 44(5 Suppl. 3):34-38. (Pubitemid 39369939)
8. BROWN EM: Calcium receptor and regulation of parathyroid hormone secretion. Rev. Endocr. Metab. Disord. (2000) 1(4):307-315.
9. BROWN EM, MACLEOD RJ: Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. (2001) 81(1):239-297. •• Review describing the pivotal role of the CaR in regulating the effects of extracellular calcium on PTH secretion.
10. D'SOUZA-LI L, YANG B, CANAFF L et al.: Identification and functional.characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. J. Clin. Endocrinol. Metab. (2002) 87(3):1309-1318.
11. JANICIC N, PAUSOVA Z, COLE DE, HENDY GN: Insertion of an Alu sequence in the Ca(2+)-sensing receptor gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Am. J. Hum. Genet. (1995) 56(4):880-886.
12. PEARCE SH, TRUMP D, WOODING C et al.: Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J. Clin. Invest. (1995) 96(6):2683-2692.
13. CONLEY YP, FINEGOLD DN, PETERS DG et al.: Three novel activating mutations in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia. Mol. Genet. Metab. (2000) 71(4):591-598.
14. BROWN EM: Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J. Clin. Endocrinol. Metab. (1983) 56(3):572-581. • Study examining the relationship between PTH release in vitro to the extracellular calcium concentration, in normal bovine and human, as well as pathological human, parathyroid tissue.
15. FELSENFELD AJ, RODRIGUEZ M, DUNLAY R, LLACH F: A comparison of parathyroid-gland function in haemodialysis patients with different forms of renal osteodystrophy. Nephrol. Dial. Transplant. (1991) 6(4):244-251.
16. DUSSO AS, BROWN AJ, SLATOPOLSKY E: Vitamin D. Am. J. Physiol. Renal Physiol. (2005) 289(1):F8-F28. •• A scholarly and comprehensive review of vitamin D metabolism and actions.
17. RODRIGUEZ M, CANALEJO A, GARFIA B, AGUILERA E, ALMADEN Y: Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int. Suppl. (2002) 80:155-160.
18. SLATOPOLSKY E, BROWN A, DUSSO A: Pathogenesis of secondary hyperparathyroidism. Kidney Int. Suppl. (1999) 73:S14-S19.
19. ARNOLD A, BROWN MF, URENA P et al.: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J. Clin. Invest. (1995) 95(5):2047-2053.
20. TOMINAGA Y, TANAKA Y, SATO K, NAGASAKA T, TAKAGI H: Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin. Surg. Oncol. (1997) 13(2):78-86.
21. MAYER GP, HABENER JF, POTTS JT Jr: Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent nonsuppressible component of secretion. J. Clin. Invest. (1976) 57(3):678-683.
22. GOGUSEV J, DUCHAMBON P, HORY B et al.: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. (1997) 51(1):328-336. (Pubitemid 27064555)
23. KIFOR O, MOORE FD, JR., WANG P et al.: Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. (1996) 81(4):1598-1606.
24. FUKUDA N, TANAKA H, TOMINAGA Y et al.: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J. Clin. Invest. (1993) 92(3):1436-1443.
25. TOKUMOTO M, TSURUYA K, FUKUDA K et al.: Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. (2002) 62(4):1196-1207.
26. MARTIN LN, KAYATH MJ, VIEIRA JG, NOSE-ALBERTI V: Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis. Histopathology (1998) 33(1):46-51. (Pubitemid 28352570)
27. KRAUSE MW, HEDINGER CE: Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum. Pathol. (1985) 16(8):772-784.
28. STEDDON SJ, CUNNINGHAM J: Calcimimetics and calcilytics-fooling the calcium receptor. Lancet (2005) 365(9478):2237-2239.
29. CLARKSON EM, MCDONALD SJ, DE WARDENER HE: The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin. Sci. (1966) 30(3):425-438.
30. MEYRIER A, MARSAC J, RICHET G: The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis. Kidney Int. (1973) 4(2):146-153.
31. GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2000) 342(20):1478-1483.
32. GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. (2000) 15(7):1014-1021.
33. BLOCK GA, SPIEGEL DM, EHRLICH J et al.: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. (2005) 68(4):1815-1824. (Pubitemid 43169927)
34. CANNATA ANDIA JB: Adynamic bone and chronic renal failure: an overview. Am. J. Med. Sci. (2000) 320(2):81-84.
35. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. (1986) 315(3):157-161.
36. MAI ML, EMMETT M, SHEIKH MS et al.: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. (1989) 36(4):690-695. (Pubitemid 19239562)
37. CHERTOW GM, BURKE SK, LAZARUS JM et al.: Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. (1997) 29(1):66-71.
38. CHERTOW GM, DILLON MA, AMIN N, BURKE SK: Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. J. Ren. Nutr. (2000) 10(3):125-132.
39. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62(1):245-252. (Pubitemid 34754068)
40. QUNIBI WY, HOOTKINS RE, MCDOWELL LL et al.: Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. (2004) 65(5):1914-1926. (Pubitemid 38591044)
41. SUKI W, ZABANEH R, CANGIANO J et al.: The DCOR trial a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. Presented at the American Society of Nephrology Renal Week. Philadelphia, PA, USA (8-13 November 2005) Abstract TH-PO745. • Preliminary report of the first large-scale, randomised trial to demonstrate a mortality and morbidity benefit of treatment for haemodialysis patients. Although the primary end point of an overall reduction in mortality was not reached, in patients treated for 2 years, sevelamer reduced all-cause mortality risk by 34% compared with calcium-based binders (p = 0.02), with older patients experiencing the greatest benefit.
42. GALLIENI M, COZZOLINO M, BRANCACCIO D: Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int. (2000) 57(4):1776-1777. (Pubitemid 30207940)
43. D'HAESE PC, SPASOVSKI GB, SIKOLE A et al.: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. Suppl. (2003) 85:S73-S78.
44. JOY MS, FINN WF: Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. (2003) 42(1):96-107.
45. HUTCHISON AJ, MAES B, VANWALLEGHEM J et al.: Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin. Pract. (2005) 100(1):c8-c19.
46. LOCATELLI F, D'AMICO M, PONTORIERO G: Lanthanum carbonate (Shire). IDrugs (2003) 6(7):688-695. (Pubitemid 36916737)
47. WEBSTER I, GILL M: Lanthanum carbonate, a new phosphorus binder, is well tolerated over a 3 year period in dialysis patients. Presented at the European Renal Association - European Dialysis and Transplantation Association Annual Meeting. Lisbon, Portugal (15-18 May 2004) Abstract SP-268 and poster.
48. SLATOPOLSKY E, LIAPIS H, FINCH J: Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. (2005) 68(6):2809-2813. (Pubitemid 43251027)
49. CANAVESE C, MEREU C, NORDIO M, SABBIONI E, AIME S: Blast from the past: the aluminum's ghost on the lanthanum salts. Curr. Med. Chem. (2005) 12(14):1631-1636.
50. BERL T, BERNS AS, HUFER WE et al.: 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann. Intern. Med. (1978) 88(6):774-780.
51. MEMMOS DE, EASTWOOD JB, TALNER LB et al.: Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br. Med. J. (1981) 282(6280):1919-1924.
52. BRANDI L, DAUGAARD H, EGSMOSE C et al.: Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia. J. Intern. Med. (1996) 239(4):353-360.
53. TENG M, WOLF M, LOWRIE E et al.: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. (2003) 349(5):446-456.
54. OWDA AK, MOUSA D, ABDALLAH AH et al.: Long-term intravenous calcitriol in secondary hyperparathyroidism: the role of technetium-99m-MIBI scintigraphy in predicting the response to treatment. Ren. Fail. (2002) 24(2):165-173.
55. RODRIGUEZ M, CARAVACA F, FERNANDEZ E et al.: Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int. (1999) 56(1):306-317. (Pubitemid 29300549)
56. MALBERTI F, CORRADI B, COSCI P et al.: Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am. J. Kidney Dis. (1996) 28(5):704-712.
57. FUKAGAWA M, KITAOKA M, YI H et al.: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron (1994) 68(2):221-228. (Pubitemid 24289741)
58. SZABO A, MERKE J, BEIER E, MALL G, RITZ E: 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. (1989) 35(4):1049-1056. • This report documents the effects of vitamin D on parathyroid cell proliferation in rats with uraemia (subtotal nephrectomy) or calcium deficiency.
59. COZZOLINO M, LU Y, FINCH J, SLATOPOLSKY E, DUSSO AS: p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. (2001) 60(6):2109-2117. (Pubitemid 33070454)
60. QUARLES LD, YOHAY DA, CARROLL BA et al.: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. (1994) 45(6):1710-1721. (Pubitemid 24207507)
61. FUKAGAWA M, OKAZAKI R, TAKANO K et al.: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N. Engl. J. Med. (1990) 323(6):421-422.
62. MOE SM, DRUEKE TB: Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am. J. Nephrol. (2003) 23(6):369-379.
63. JONO S, NISHIZAWA Y, SHIOI A, MORII H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation (1998) 98(13):1302-1306.
64. HENLEY C, COLLOTON M, CATTLEY RC et al.: 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol. Dial. Transplant. (2005) 20(7):1370-1377.
65. MOE SM, O'NEILL KD, DUAN D et al.: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. (2002) 61(2):638-647. (Pubitemid 34102607)
66. SHALHOUB V, SHATZEN E, HENLEY C et al.: Microarray analysis implicates cytokine and wnt signalling pathways in bovine aorta smooth muscle cells that calcify in the presence of calcitriol and paricalcitol in vitro. ERA-EDTA 2005 - European Renal Association - European Dialysis and Transplantation Association. Istanbul, Turkey, 4-7 June (Abstract M026 and Poster) Nephrol. Dial. Transplantat. (2005) 20(Suppl. 5):V196.
67. BROWN AJ, DUSSO AS, SLATOPOLSKY E: Vitamin D analogues for secondary.hyperparathyroidism. Nephrol. Dial. Transplant. (2002) 17(Suppl. 10):10-19.
68. DUSSO AS: Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int. Suppl. (2003) 85:S6-S9.
69. SPRAGUE SM, LLACH F, AMDAHL M, TACCETTA C, BATLLE D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. (2003) 63(4):1483-1490. (Pubitemid 36350014)
70. SHOJI T, SHINOHARA K, KIMOTO E et al.: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. (2004) 19(1):179-184.
71. TENG M, WOLF M, OFSTHUN MN et al.: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. (2005) 16(4):1115-1125. • This historical cohort study examined mortality in over 51,000 chronic haemodialysis patients and found that the group that received injectable vitamin D had a significant survival advantage over patients who did not.
72. DE FRANCISCO AL: Cinacalcet HCl: a novel therapeutic for hyperparathyroidism. Expert Opin. Pharmacother. (2005) 6(3):441-452. •• Review of the calcimimetic agent cinacalcet HCl: pharmacokinetics, efficacy and tolerability. In addition to data evaluating the drug in SHPT, evidence suggesting the utility of cinacalcet in patients with primary HPT, including parathyroid carcinoma, and the potential for additional therapeutic applications, is also discussed.
73. NEMETH EF, STEFFEY ME, HAMMERLAND LG et al.: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl Acad. Sci.USA (1998) 95(7):4040-4045.
74. LEVI R, GABERMAN E, SILVER J, MARTIN D, NAVEH-MANY T: The calcimimetic NPS R-568 decreases PTH gene expression in rats with secondary hyperparathyroidism due to experimental uremia. ERA-EDTA 2005 - European Renal Association - European Dialysis and Transplantation Association. Istanbul, Turkey, 4-7 June (Abstract SP014 and Poster). Nephrol. Dial. Transplant. (2005) 20(Suppl. 5):v24.
75. GOODMAN WG, HLADIK GA, TURNER SA et al.: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. (2002) 13(4):1017-1024.
76. BROWN EM: Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr. Opin. Nephrol. Hypertens. (1993) 2(4):541-551.
77. COLLOTON M, SHATZEN E, MILLER G et al.: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. (2005) 67(2):467-476. • This represents the first full publication documenting the inhibitory effects of cinacalcet HCl on PTH in a rodent model of CKD. (Pubitemid 40139838)
78. CHIN J, MILLER SC, WADA M et al.: Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J. Am. Soc. Nephrol. (2000) 11(5):903-911.
79. WADA M, FURUYA Y, SAKIYAMA J et al.: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. (1997) 100(12):2977-2983.
80. MIZOBUCHI M, HATAMURA I, SAJI F et al.: The linkage between the parathyroid cell proliferation and the expressions of calcium sensing and vitamin D receptor by calcimimetics in uremic rats. J. Am. Soc. Nephrol. (2003) 14:464A.
81. MIZOBUCHI M, HATAMURA I, OGATA H et al.: Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J. Am. Soc. Nephrol. (2004) 15(10):2579-2587.
82. ALMADEN Y, RODRIGUEZ M, CANALEJO A et al.: The calcimimetic NPS R-568 increases parathyroid vitamin D receptor (VDR) mRNA expression in vitro and in vivo. ERA-EDTA 2005 - European Renal Association - European Dialysis and Transplantation Association. Istanbul, Turkey, 4-7 June (Abstract SP017 and Poster). Nephrol. Dial. Transplant. (2005) 20:V25.
83. LINDBERG JS, MOE SM, GOODMAN WG et al.: The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. (2003) 63(1):248-254. (Pubitemid 35463928)
84. LINDBERG JS, CULLETON B, WONG G et al.: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J. Am. Soc. Nephrol. (2005) 16(3):800-807.
85. QUARLES LD, SHERRARD DJ, ADLER S et al.: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J. Am. Soc. Nephrol. (2003) 14(3):575-583.
86. BLOCK GA, MARTIN KJ, DE FRANCISCO AL et al.: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. (2004) 350(15):1516-1525. •• This report presents pooled data from two identical randomised, double-blind, placebo-controlled Phase III trials evaluating the safety and efficacy of cinacalcet HCl.
87. SILVERBERG SJ, BONE HG III, MARRIOTT TB et al.: Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med. (1997) 337(21):1506-1510.
88. MOE SM, CHERTOW GM, COBURN JW et al.: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. (2005) 67(2):760-771. (Pubitemid 40139871)
89. CUNNINGHAM J, URENA P, REICHEL H et al.: Long term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (ESRD). ERA-EDTA 2005 - European Renal Association - European Dialysis and Transplantation Association. Istanbul, Turkey, 4-7 June (Abstract SP210 and Poster). Nephrol. Dial. Transplant. (2005) 20(Suppl. 5):V89.
90. MOE SM, CUNNINGHAM J, BOMMER J et al.: Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol. Dial. Transplant. (2005) 20(10):2186-2193.
91. CHERTOW GM, BLUMENTHAL S, TURNER S et al.: cinacalcet hydrochloride (sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium X phosphate. Clin. J. Am. Soc. Nephrol. (2006) 1(2):305-312.
92. MESSA P, MOTELLON J, TEAM OS: Optimizing the use of cinacalcet (MimparaR/SensiparR) and Vitamin D: Results from the OPTIMA Study. American Society of Nephrology Renal Week 2005. November 8-13, Philadelphia, Pennsylvania (Abstract F-PO758 and Poster). J. Am. Soc. Nephrol. (2005) 16(Oct):501A.
93. ISHIZUYA T, YOKOSE S, HORI M et al.: Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. (1997) 99(12):2961-2970.
94. WADA M, ISHII H, FURUYA Y et al.: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. (1998) 53(2):448-453. (Pubitemid 28097862)
95. OGATA H, RITZ E, ODONI G, AMANN K, ORTH SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J. Am. Soc. Nephrol. (2003) 14(4):959-967.
96. LOPEZ I, AGUILERA-TEJERO E, MENDOZA FJ et al.: Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J. Am. Soc. Nephrol. (2006) 17(3):795-804.
97. CUNNINGHAM J, DANESE M, OLSON K, KLASSEN P, CHERTOWGM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. (2005) 68(4):1793-1800. (Pubitemid 43169924)
98. MALLUCHE H, MONIER-FAUGERE M, WANG G et al.: Cinacalcet HCL reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism. ERA-EDTA 2004 - European Renal Association - European Dialysis and Transplantation Association. Lisbon, Portugal, 15-18 May (Abstract MO16 and Poster). Nephrol. Dial. Transplant. (2004):218b.
99. FUKAGAWA M, KITAOKA M, KUROKAWA K: Resistance of the parathyroid glands to vitamin D in renal failure: implications for medical management. Kidney Int. Suppl. (1997) 62:S60-S64.
100. MARTIN KJ, OLGAARD K, COBURN JW et al.: Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am. J. Kidney Dis. (2004) 43(3):558-565.
101. GOODMAN WG: The evolution of assays for parathyroid hormone. Semin. Dial. (2005) 18(4):296-301.
102. SALUSKY IB, GOODMAN WG: Adynamic renal osteodystrophy: is there a problem? J. Am. Soc. Nephrol. (2001) 12(9):1978-1985.
103. CHARYTAN C, COBURN JW, CHONCHOL M et al.: Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis. (2005) 46(1):58-67.
104. SRINIVAS TR, SCHOLD JD, WOMER KL et al.: Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J. Am. Soc. Nephrol. (2006) 1(2):323-326.
105. KRUSE AE, EISENBERGER U, FREY FJ, MOHAUPT MG: The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol. Dial. Transplant. (2005) 20(7):1311-1314.
106. CUNNINGHAM J: Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol. Dial. Transplant. (2004) 19(Suppl. 5):V9-V14.